Scarica l'app Stockscreener
22.51
3.02%
-0.70
Dopo l'orario di chiusura:
22.72
0.21
+0.93%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RARE Giù?
Forum
Previsione
Frazionamento azionario
Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie
Can Ultragenyx Pharmaceutical Inc. stock rebound after recent weaknessMarket Movers & Fast Momentum Entry Tips - ulpravda.ru
Why Ultragenyx Pharmaceutical Inc. stock is trending among retail tradersPrice Action & Low Risk Entry Point Guides - ulpravda.ru
Analysts Lower Ultragenyx (RARE) Target but Stay Bullish - Insider Monkey
Looking Into Ultragenyx Pharmaceutical Inc's Recent Short Interest - Sahm
Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
RARE ALERT: Ongoing Investigation Into Ultragenyx Pharmaceutical Inc.Contact Levi & Korsinsky - ACCESS Newswire
Ongoing Investigation into Ultragenyx Pharmaceutical Inc. (RARE): Contact Levi & Korsinsky About Potential Fraud - ACCESS Newswire
12 Stocks that Will Bounce Back According to Wall Street Analysts - Insider Monkey
How Ultragenyx Pharmaceutical Inc. stock valuations compare to rivals2025 Volatility Report & Safe Entry Trade Reports - ulpravda.ru
2026-01-08 | Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:RARE | Press Release - Stockhouse
Is Ultragenyx Pharmaceutical Inc. (UP0) stock a buy before earnings results2025 Dividend Review & AI Based Trade Execution Alerts - ulpravda.ru
Looking at the Latest Short Interest Activity for Ultragenyx Pharmaceutical Inc - Bitget
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - MarketScreener
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - PR Newswire
RBC Cuts Price Target on Ultragenyx Pharmaceutical to $35 From $72, Keeps Outperform, Speculative Risk - MarketScreener
Kyowa Kirin and Ultragenyx to proceed with US regulatory bid for burosumab - The Pharma Letter
Ultragenyx Pharmaceutical Inc. CEO to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Does Ultragenyx Pharmaceutical Inc. (UP0) stock trade below intrinsic valueCandlestick Trading Patterns & Affordable Trading Growth - ulpravda.ru
2026-01-07 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Investors to Connect | NDAQ:RARE | Press Release - Stockhouse
What is HC Wainwright's Estimate for RARE FY2025 Earnings? - MarketBeat
Biggest stock movers Monday: DigitalBridge, Ultragenyx Pharmaceutical - MSN
Ongoing Securities Investigation into Ultragenyx Pharmaceutical Inc. (RARE)Contact Levi & Korsinsky - ACCESS Newswire
MarketsMedicine Hat News - FinancialContent
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx ... - Bluefield Daily Telegraph
Ultragenyx Pharma stock price target lowered to $60 at H.C. Wainwright - Investing.com Nigeria
Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: A 197% Upside Potential that Grabs Investor Attention - DirectorsTalk Interviews
Insider Sell: Howard Horn Sells Shares of Ultragenyx Pharmaceuti - GuruFocus
ATTENTION Ultragenyx Pharmaceutical Inc. (RARE) Investors: Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Ultragenyx recovers some losses as Jefferies sees potential 2026 rebound - MSN
Ultragenyx Finishes Rolling Submission of BLA for Glycogen Storage Disease Gene Therapy DTX401 - CGTLive®
Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ultragenyx Pharmaceutical Inc. (RARE) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Ultragenyx Pharmaceutical (RARE) Target Price Lowered by HC Wain - GuruFocus
HC Wainwright Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $60.00 - MarketBeat
Guggenheim lowers Ultragenyx Pharma stock price target on trial failures By Investing.com - Investing.com Nigeria
2026-01-05 | Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:RARE | Press Release - Stockhouse
Ultragenyx Pharmaceutical (RARE): Guggenheim Lowers Price Target - GuruFocus
Guggenheim lowers Ultragenyx Pharma stock price target on trial failures - Investing.com
Guggenheim Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Ultragenyx Pharmaceutical (RARE) Advances Gene Therapies, But How Durable Is Its Rare-Disease Strategy? - Yahoo Finance
Ultragenyx Pharmaceutical (RARE) Is Down 31.0% After Rare-Disease Milestone UpdatesHas The Bull Case Changed? - Sahm
Ultragenyx completes rolling FDA submission for US approval of gene therapy - MSN
StockWatch: Ultragenyx, Mereo Plummet on Brittle Bone Candidate Failures - Genetic Engineering and Biotechnology News
ATTENTION RARE Shareholders: Lost Money on Ultragenyx Pharmaceutical Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Ultragenyx granted FDA priority review for gene therapy in rare brain disorder - MSN
Benzinga Bulls And Bears: Nike, SpaceX, Ultragenyx — And Chinese Tech Stocks Slide - Benzinga
Ultragenyx stock eyes best day in 17 months as Wall Street shifts focus to 2026 pipeline after bone disease trial miss - MSN
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), FibroBiologics, Inc. (FBLG) and Corcept Therapeutics (CORT) - The Globe and Mail
Levi & Korsinsky Investigates Possible Securities Fraud by Ultragenyx Pharmaceutical Inc. (RARE) - ACCESS Newswire
Ultragenyx Phase III Data Reveal Limits of Bone Density Endpoints in Rare Bone Disease - BioPharm International
Bank of America Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $58.00 - MarketBeat
Ultragenyx Pharmaceutical (RARE): B of A Securities Lowers Price Target | RARE Stock News - GuruFocus
Ultragenyx completes rolling submission of BLA for DTX401 - The Pharma Letter
Ultragenyx Pharmaceuticals Loses $1 Billion in Market Value After Bone Drug Fails Phase III Trials - geneonline.com
BofA Securities lowers Ultragenyx Pharma stock price target on failed trials By Investing.com - Investing.com South Africa
Ultragenyx Loses $1B in Market Value as Bone Drug Fails To Reduce Fractures - BioSpace
These nine Bay Area drug makers are hurtling toward key FDA approval decisions in 2026 - The Business Journals
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):